TB Alliance Convenes Community Engagement Stakeholders to Discuss Clinical Trial Updates
TB Alliance’s Community Engagement (CE) forums provide an opportunity for capacity building and for members of TB-affected communities to share
TB Alliance’s Community Engagement (CE) forums provide an opportunity for capacity building and for members of TB-affected communities to share
TB Alliance has built the largest portfolio of potential new tuberculosis (TB) treatments in history. Since inception, it has introduced
When TB Alliance was formed, there had been no late-stage tuberculosis (TB) research trials conducted to modern standards. In addition
NEW YORK (July 15, 2021)—To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions
TB Alliance’s ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure
TOKYO and NEW YORK (March 31, 2021)—Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and
March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal
PRETORIA (24 March 2021)—TB Alliance welcomes today’s announcement of the early closing of randomization into the TB-PRACTECAL study. TB-PRACTECAL is a
NEW YORK (March 23, 2021) – Interested researchers are invited to apply to access the MARK-TB (Markedly Accelerating Research with
Throughout TB Alliance’s history, it has expanded its pursuit and advocacy for various types of TB research, as it identifies